{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:18:49Z","timestamp":1793999929649,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006280","name":"Urology Care Foundation","doi-asserted-by":"publisher","award":["629004"],"award-info":[{"award-number":["629004"]}],"id":[{"id":"10.13039\/100006280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.urolonc.2020.12.025","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T18:31:07Z","timestamp":1611253867000},"page":"498.e13-498.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non\u2013muscle invasive bladder cancer during BCG shortage"],"prefix":"10.1016","volume":"39","author":[{"given":"Dominic C.","family":"Grimberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dudinec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankeet","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brant A.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2020.12.025_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.12.025_bib0003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2012.08.064","article-title":"Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer","volume":"63","author":"Thomas","year":"2012","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2020.12.025_bib0005","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","article-title":"NCCN guidelines insights: bladder cancer, Version 5.2018","volume":"16","author":"Flaig","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0007","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.12.025_bib0008","doi-asserted-by":"crossref","unstructured":"Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2(1):27-36. doi:10.3233\/BLC-150034","DOI":"10.3233\/BLC-150034"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2020.12.025_bib0010","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a neta-analysis of the published results of Randomized Clinical Trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0011","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille calmette-gu\u00e9rin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0012","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0013","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non\u2013muscle-invasive bladder cancer during the current worldwide shortage of Bacille Calmette-Gu\u00e9rin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.12.025_bib0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11934-019-0952-y","article-title":"Current clinical trials in non-muscle-invasive bladder cancer: heightened need in an era of chronic BCG shortage","volume":"20","author":"Packiam","year":"2019","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOU.0000000000000739","article-title":"Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Gu\u00e9rin shortage","volume":"30","author":"Fankhauser","year":"2020","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0016","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"issue":"1","key":"10.1016\/j.urolonc.2020.12.025_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0018","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo\u00ae working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.12.025_bib0019","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Contr Clin Trials"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","article-title":"Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma","volume":"52","author":"Paroni","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0022","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0023","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hypertherm"},{"issue":"4S","key":"10.1016\/j.urolonc.2020.12.025_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2017.02.503","article-title":"Clinical Trials Group HIVEC I and HIVEC II. Mp15-18 safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in hivec i and hivec ii: an analysis of 307 patients","volume":"197","author":"Tan","year":"2017","journal-title":"J Urol."},{"issue":"6","key":"10.1016\/j.urolonc.2020.12.025_bib0025","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non\u2013muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2020.12.025_bib0026","unstructured":"Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.:7."},{"issue":"4S","key":"10.1016\/j.urolonc.2020.12.025_bib0027","volume":"189","author":"Gerson","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.12.025_bib0028","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2020.12.025_bib0029","doi-asserted-by":"crossref","unstructured":"van Valenberg FJP, Kajtazovic A, Canepa G, et al. Intravesical radiofrequency-induced chemohyperthermia for carcinoma in situ of the urinary bladder: a retrospective multicentre study. Bladder Cancer. 4(4):365-376. doi:10.3233\/BLC-180187","DOI":"10.3233\/BLC-180187"},{"issue":"3","key":"10.1016\/j.urolonc.2020.12.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003231","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","author":"Shelley","year":"2003","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920306542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920306542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:22:58Z","timestamp":1761042178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920306542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1078143920306542"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.025","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non\u2013muscle invasive bladder cancer during BCG shortage","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}